LINCOLN PHARMACEUTICALS
|
LINCOLN PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 43.88 | 41.11 | 46.58 | 36.40 | 34.63 |
| CEPS(Rs) | 51.12 | 47.55 | 51.89 | 40.97 | 38.66 |
| DPS(Rs) | 1.80 | 1.80 | 1.80 | 1.50 | 1.50 |
| Book NAV/Share(Rs) | 378.25 | 335.34 | 295.98 | 250.86 | 216.12 |
| Tax Rate(%) | 23.98 | 24.58 | 23.67 | 27.45 | 27.71 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.93 | 15.55 | 16.46 | 16.68 | 19.23 |
| EBIT Margin(%) | 16.64 | 17.02 | 20.38 | 19.17 | 19.61 |
| Pre Tax Margin(%) | 16.49 | 16.73 | 20.14 | 18.79 | 19.32 |
| PAT Margin (%) | 12.54 | 12.62 | 15.37 | 13.63 | 13.97 |
| Cash Profit Margin (%) | 14.61 | 14.59 | 17.12 | 15.35 | 15.60 |
| Performance Ratios | |||||
| ROA(%) | 10.11 | 10.64 | 13.70 | 12.24 | 13.31 |
| ROE(%) | 12.30 | 13.02 | 17.04 | 15.59 | 17.35 |
| ROCE(%) | 16.27 | 17.55 | 22.53 | 21.82 | 24.29 |
| Asset Turnover(x) | 0.81 | 0.84 | 0.89 | 0.90 | 0.95 |
| Sales/Fixed Asset(x) | 2.66 | 2.67 | 2.80 | 2.90 | 3.17 |
| Working Capital/Sales(x) | 1.49 | 1.66 | 1.76 | 1.81 | 1.89 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.38 | 0.37 | 0.36 | 0.34 | 0.32 |
| Receivable days | 85.34 | 91.75 | 89.63 | 86.09 | 84.27 |
| Inventory Days | 41.33 | 43.57 | 44.26 | 48.72 | 43.86 |
| Payable days | 146.25 | 141.73 | 110.27 | 124.63 | 138.44 |
| Valuation Parameters | |||||
| PER(x) | 12.86 | 13.42 | 12.57 | 9.31 | 8.98 |
| PCE(x) | 11.04 | 11.60 | 11.28 | 8.27 | 8.04 |
| Price/Book(x) | 1.49 | 1.64 | 1.98 | 1.35 | 1.44 |
| Yield(%) | 0.32 | 0.33 | 0.31 | 0.44 | 0.48 |
| EV/Net Sales(x) | 1.64 | 1.74 | 2.00 | 1.27 | 1.28 |
| EV/Core EBITDA(x) | 8.40 | 8.73 | 8.63 | 5.79 | 5.75 |
| EV/EBIT(x) | 9.45 | 9.74 | 9.38 | 6.30 | 6.23 |
| EV/CE(x) | 1.45 | 1.61 | 1.95 | 1.28 | 1.09 |
| M Cap / Sales | 1.68 | 1.77 | 2.02 | 1.33 | 1.32 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 7.67 | 7.35 | 13.76 | 8.09 | 11.30 |
| Core EBITDA Growth(%) | 5.78 | -7.71 | 20.29 | 5.88 | 13.61 |
| EBIT Growth(%) | 5.01 | -10.21 | 20.68 | 5.26 | 14.20 |
| PAT Growth(%) | 6.74 | -11.74 | 27.99 | 5.11 | 11.41 |
| EPS Growth(%) | 6.74 | -11.74 | 27.99 | 5.11 | 11.41 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | - | - | - | - |
| Current Ratio(x) | 4.45 | 4.00 | 3.94 | 4.07 | 3.37 |
| Quick Ratio(x) | 3.87 | 3.40 | 3.29 | 3.34 | 2.71 |
| Interest Cover(x) | 115.14 | 58.99 | 84.45 | 50.50 | 67.11 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of LINCOLN PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LINCOLN PHARMACEUTICALS | ₹1,164.3 Cr | -1.7% | -3.7% | 7.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹434,280.0 Cr | -1.8% | -7% | 14.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,737.0 Cr | -3.4% | 0.4% | 58.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,129.0 Cr | -2.7% | -3.6% | 36% | Stock Analytics | |
| CIPLA | ₹108,808.0 Cr | -3.9% | -4.7% | -10.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,170.0 Cr | 3% | 6.1% | -3.8% | Stock Analytics | |
LINCOLN PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LINCOLN PHARMACEUTICALS | -1.7% |
-3.7% |
7.4% |
| SENSEX | -2.3% |
-6.6% |
-12% |
You may also like the below Video Courses
